Posted by Michael Wonder on 18 Feb 2026
Moderna receives European Commission marketing authorisation for COVID-19 vaccine mNEXSPIKE
17 February 2026 - mNEXSPIKE is the third Moderna vaccine authorised in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe.
Moderna today announced that the European Commission has granted marketing authorisation for mNEXSPIKE (mRNA-1283), a new COVID vaccine, for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older.
